60 Degrees Pharmaceuticals Receives Additional U.S. Patent Covering Tafenoquine for Prevention of Plasmodium Falciparum Malaria
August 22, 2023 07:31 ET
|
Sixty Degrees Pharmaceuticals
60P was awarded additional U.S. patent protection to further solidify its exclusive rights through 2035 for tafenoquine for prevention of Plasmodium falciparum malaria in naïve individualsTafenoquine...
60 Degrees Pharmaceuticals Registers ACLR8-LR, a Phase IIB Study of Tafenoquine for Treatment of COVID-19, on ClinicalTrials.gov
August 15, 2023 07:31 ET
|
Sixty Degrees Pharmaceuticals
ACLR8-LR, a double-blind, randomized, placebo-controlled Phase IIB study to determine efficacy of the ARAKODA® regimen of tafenoquine in COVID-19 patients with mild-moderate symptoms and low risk of...
VoIP-Pal Has Stipulated to Dismissal of All Legal Actions in the Northern District of California Against Google, Facebook, and Twitter
June 07, 2023 08:00 ET
|
Voip-Pal.Com Inc.
WACO, Texas, June 07, 2023 (GLOBE NEWSWIRE) -- VoIP-Pal.com Inc. (“VoIP-Pal”, “Company”) (OTCQB: VPLM) has filed stipulations with Facebook, Google, and Twitter dismissing the lawsuits against these...
Ocean Biomedical (NASDAQ: OCEA) Announces Notice of Allowance for U.S. Patent Application for Breakthrough Pulmonary Fibrosis Treatments Issued to Scientific Co-founder Dr. Jack A. Elias.
April 20, 2023 08:01 ET
|
Ocean Biomedical, Inc.
Providence, RI, April 20, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development and commercialization of scientifically compelling...
Ocean Biomedical (NASDAQ: OCEA) Announces Notice of Allowance for U.S. Patent Application for Developing “Whole New Class” of Malaria Therapeutics Issued to Scientific Co-founder Dr. Jonathan Kurtis
April 13, 2023 08:01 ET
|
Ocean Biomedical, Inc.
Providence, RI, April 13, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development and commercialization of scientifically compelling...
Aeterna Zentaris Provides Update on Macrilen® (Macimorelin), Reiterates Advancement of Pediatric DETECT Trial
April 05, 2023 07:55 ET
|
Aeterna Zentaris Inc
U.S. sales of Macrilen® for adult use to be temporarily discontinued as of May 23, 2023, while DETECT trial continues in order to expand the opportunity for pediatric usage of Macrilen®Sales and...
Rare Earth Elements Collected from Wastewater Utilizing Cyanobacteria Now Patent Pending
March 15, 2023 06:00 ET
|
Yasheng Group
SAN JOSE, March 15, 2023 (GLOBE NEWSWIRE) -- SAN JOSE, CA--(March 15, 2023) - Yasheng Group, (OTC: HERB), an agricultural and biotech company with U.S. headquarters in San Jose, California today...
VoIP-Pal Receives Favorable Claim Construction Ruling in its Patent Infringement Case Against Samsung
January 09, 2023 08:00 ET
|
Voip-Pal.Com Inc.
WACO, Texas, Jan. 09, 2023 (GLOBE NEWSWIRE) -- VoIP-Pal.com Inc. (“VoIP-Pal”, “Company”) (OTCQB: VPLM) is pleased to announce the Company has received a favorable result in the Claim Construction...
Standard Lithium Receives Notice of Allowance for Final U.S. Patent Covering DLE Process for Recovering Lithium From Brines
December 29, 2022 06:00 ET
|
Standard Lithium
VANCOUVER, British Columbia, Dec. 29, 2022 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV: SLI) (NYSE American: SLI) (FRA: S5L), a leading near-commercial...
Standard Lithium Receives Notice of Allowance for Final U.S. Patent Covering DLE Process for Recovering Lithium From Brines
December 29, 2022 03:01 ET
|
Standard Lithium
VANCOUVER, British Columbia, Dec. 29, 2022 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV: SLI) (NYSE American: SLI) (FRA: S5L), a leading near-commercial...